MEF2D Protein - Myocyte Enhancer Factor 2D <table class="infobox infobox-protein">
MEF2D Protein — Myocyte Enhancer Factor 2D
Introduction Mef2D Protein Myocyte Enhancer Factor 2D is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview ...
MEF2D Protein - Myocyte Enhancer Factor 2D <table class="infobox infobox-protein">
MEF2D Protein — Myocyte Enhancer Factor 2D
Introduction Mef2D Protein Myocyte Enhancer Factor 2D is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview MEF2D (Myocyte-specific enhancer factor 2D) is a transcription factor protein encoded by the [MEF2D gene](/genes/mef2d). It belongs to the MEF2 family of transcription factors, which are essential for neuronal development, survival, synaptic plasticity, and activity-dependent gene expression.[@mao1999]
The protein is a DNA-binding protein that recognizes the Mef2 consensus sequence (TTATTTATA) and regulates target gene expression in response to neuronal activity and various signaling pathways.
Structure
Domain Architecture MEF2D contains several functional domains:
MADS-box domain (MHF1 region) : Amino acids 1-56 - DNA-binding and dimerization domainMEF2 domain : Amino acids 85-127 - Protein-protein interactions and cofactor bindingTransactivation domain (TAD) : Carboxy-terminal region - Contains serine-rich and acidic regions for transcriptional activationSerine-rich region : Multiple serine residues that can be phosphorylated
Post-Translational Modifications MEF2D undergoes several post-translational modifications:
Phosphorylation : Multiple serine/threonine kinases phosphorylate MEF2D, including CaMK, MAPK, and PKCAcetylation : p300/CBP can acetylate MEF2D, affecting its transcriptional activitySumoylation : MEF2D can be sumoylated, which typically represses its activityProteolytic cleavage : Caspase cleavage generates truncated forms with pro-apoptotic activityNormal Function
Transcriptional Regulation MEF2D is a transcriptional activator that regulates genes involved in:
Neuronal survival : Activates expression of anti-apoptotic proteins and neurotrophic factorsSynaptic plasticity : Controls genes encoding synaptic vesicle proteins, PSD proteins, and ion channelsMetabolism : Regulates genes involved in mitochondrial function and energy metabolismCell differentiation : Controls neuronal differentiation and maturation programsSignaling Pathways MEF2D integrates signals from multiple pathways:
Calcium signaling : Ca2+/calmodulin-dependent kinases (CaMK) activate MEF2MAPK/ERK pathway : ERK signaling enhances MEF2 transcriptional activityPI3K/Akt pathway : Akt phosphorylates and activates MEF2cAMP signaling : PKA can modulate MEF2 activityRole in Disease
Parkinson's Disease In Parkinson's disease, MEF2D function is impaired in dopaminergic [neurons](/entities/neurons). Studies show:
MEF2D activity is reduced in PD models
MEF2D interacts with Parkin and PINK1, proteins involved in mitophagy
Restoring MEF2D protects neurons from mitochondrial toxins
MEF2D regulates expression of dopaminergic neuron-specific genes
Amyotrophic Lateral Sclerosis (ALS) MEF2D dysregulation contributes to motor neuron degeneration in ALS:
Altered MEF2D expression and activity in ALS models
MEF2D regulates genes important for motor neuron survival
Therapeutic approaches targeting MEF2D are being explored
Alzheimer's Disease MEF2 is involved in synaptic dysfunction in AD:
MEF2 activity is altered in AD models
MEF2 regulates synaptic plasticity genes affected in AD
Huntington's Disease MEF2D function is impaired in HD:
Transcriptional dysregulation of MEF2 target genes
MEF2D mediates some effects of mutant [huntingtin](/proteins/huntingtin)
Therapeutic Targeting
Small Molecule Activators Research is exploring small molecules that can enhance MEF2D activity:
Compounds that increase MEF2D phosphorylation
Histone deacetylase (HDAC) inhibitors that enhance MEF2D-mediated transcription
Gene Therapy Approaches
Viral vectors expressing MEF2D
CRISPR-based approaches to enhance MEF2D expression
Drug Targets Key kinases that regulate MEF2D activity are potential drug targets:
CaMK inhibitors/activators
MAPK pathway modulators
Key Publications
[Neuronal activity-dependent cell survival mediated by transcription factor MEF2](https://doi.org/10.1126/science.286.5447.785). Science , 1999.
[Activity-dependent regulation of MEF2 transcription factors in the nervous system](https://doi.org/10.1101/gad.1459106). Genes & Development , 2006.
[Myocyte enhancer factor 2D mediates mitochondria-dependent apoptosis in Parkinson's disease](https://doi.org/10.1016/j.neurobiolaging.2014.04.022). Neurobiology of Aging , 2014.
[MEF2D polymorphisms and susceptibility to amyotrophic lateral sclerosis](https://doi.org/10.1371/journal.pone.0120674). PLOS ONE , 2015.
External Links
UniProt : [https://www.uniprot.org/uniprot/Q01484](https://www.uniprot.org/uniprot/Q01484)PDB : [https://www.ebi.ac.uk/pdbe/entry/pdb/1bx6](https://www.ebi.ac.uk/pdbe/entry/pdb/1bx6)NCBI Protein : [https://www.ncbi.nlm.nih.gov/protein/NP_001122397](https://www.ncbi.nlm.nih.gov/protein/NP_001122397)See Also
[MEF2D Gene](/genes/mef2d)
[Proteins Index](/proteins)
[Transcription Factors](/mechanisms/transcription-regulation)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)
Background The study of Mef2D Protein Myocyte Enhancer Factor 2D has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Mao Z et al., Neuronal activity-dependent cell survival mediated by transcription factor MEF2, Science , 1999 (1999)](https://doi.org/10.1126/science.286.5447.785)
[Flavell SW et al., Activity-dependent regulation of MEF2 transcription factors in the nervous system, Genes & Development , 2006 (2006)](https://doi.org/10.1101/gad.1459106)
[Yang Y et al., Myocyte enhancer factor 2D mediates mitochondria-dependent apoptosis in Parkinson's disease, Neurobiology of Aging , 2014 (2014)](https://doi.org/10.1016/j.neurobiolaging.2014.04.022)
[Zhang Z et al., MEF2D polymorphisms and susceptibility to amyotrophic lateral sclerosis, PLOS ONE , 2015 (2015)](https://doi.org/10.1371/journal.pone.0120674)
UniProt:, MEF2D (n.d.) Show full description